Cromos Pharma, where the patients are

R&D Trends

Potential Parkinson's Therapy secures $23M for testing from NIH

Monday, March 31, 2014 01:40 PM

Results of a study funded by the Michael J. Fox Foundation (MJFF) for Parkinson's Research have enabled researchers to secure a $23 million grant from the NIH, continuing a repurposed drug approved for hypertension to phase III testing for slowing Parkinson's progression. The trial investigating the compound isradipine will be the most advanced, current study into a disease-modifying therapy for Parkinson's disease (PD), an unmet need.

More... »

CRF Health eCOA webinar series

AstraZeneca, Shenzhen University Health Science Center to collaborate

Monday, March 31, 2014 01:37 PM

AstraZeneca has announced a research collaboration with Shenzhen University Health Science Center. The partners will undertake preclinical research focused on chronic kidney disease (CKD), which represents a large and growing unmet medical need in China.

More... »

North Shore InnoVentures receives $1.65M from Massachusetts Life Sciences Center

Monday, March 31, 2014 01:29 PM

North Shore InnoVentures (NSIV), a New England technology incubator and business accelerator, has received a capital grant of $1.65 million from the Massachusetts Life Sciences Center (MLSC). The grant will allow NSIV to expand its current laboratory facilities over the next three years and purchase advanced analytical instrumentation. This grant is part of a larger $5 million award to the Life Sciences Consortium of the North Shore (LSCNS), consisting of Endicott College, Gordon College, North Shore InnoVentures, North Shore Community College and Salem State University, that will fund major lab/facility and equipment upgrade projects at the member institutions and organizations.

More... »

Praziquantel Consortium aims to fight schistosomiasis in pre-schoolers

Friday, March 28, 2014 03:18 PM

Brazilian Farmanguinhos, part of Fiocruz, and U.K.-based Simcyp are reinforcing the international nonprofit Pediatric Praziquantel Consortium. The aim of the consortium is to develop and register a new pediatric formulation against schistosomiasis for preschool-age children, a group currently lacking a suitable treatment. 

More... »

Report: Nearly 40 new medicines in development for Parkinson’s disease

Friday, March 28, 2014 03:17 PM

America’s biopharmaceutical research companies currently are developing 37 innovative new medicines to help the estimated 10 million people worldwide living with Parkinson’s disease. These medicines in development, all either in clinical trials or under review by the FDA, include 23 for Parkinson’s disease, 11 for related conditions and three diagnostics, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

More... »

National MS Society invests $29M in 83 research projects

Friday, March 28, 2014 03:13 PM

The National Multiple Sclerosis Society has committed $29 million to support an expected 83 new MS research projects and training awards. These are part of a comprehensive research strategy aimed at stopping MS, restoring function that has been lost and ending the disease forever.

More... »

GSK, EMBL-EBI, Wellcome Trust form ‘big data’ research initiative

Friday, March 28, 2014 03:09 PM

A pioneering public-private research initiative between GlaxoSmithKline, the European Bioinformatics Institute (EMBL-EBI) and the Wellcome Trust Sanger Institute has formed to harness the power of “big data” and genome sequencing to improve the success rate for discovering new medicines. The new Center for Therapeutic Target Validation (CTTV) will aim to address a wide range of human diseases and will share its data openly in the interests of accelerating drug discovery.

More... »

Report: Drug developers drawn to orphan drugs market, create competitive pipelines

Friday, March 28, 2014 03:08 PM

New analysis from Frost & Sullivan's Product and Pipeline Assessment of the Global Orphan Drugs Market identifies rare cancers as the orphan therapeutic area with the highest level of drug development activity. Other disease areas witnessing considerable drug development activity include blood/lymphatic system diseases, infectious/parasitic diseases, neurological diseases, metabolic diseases and immunological/inflammatory diseases.

More... »

BARDA awards SwRI $8.3M to continue developing cyanide poisoning antidote

Wednesday, March 26, 2014 11:45 AM

The U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) has awarded Southwest Research Institute (SwRI), an independent, nonprofit, applied R&D organization, an $8.3 million contract extension to continue development of a nasal-delivery, first-line treatment system to combat cyanide poisoning using an intranasal formulation of isoamyl nitrite.

More... »

Spark Therapeutics, Genable Technologies collaborate

Wednesday, March 26, 2014 11:41 AM

Spark Therapeutics of Philadelphia and Genable Technologies, a privately held Dublin, Ireland-based biopharmaceutical company, are collaborating on Genable's lead therapeutic GT038, used to treat rhodopsin-linked autosomal dominant retinitis pigmentosa (RHO adRP). Genable will license certain adeno-associated virus (AAV) vector manufacturing patents from Spark. Spark will be the exclusive manufacturer of the product and provide development advice and experience to Genable to help in the ongoing development of GT038. Spark will receive milestone payments and royalties on future sales of GT038.

More... »

CenterWatch Drugs in Clinical Trials



Browse by:


April 21

Healthcare IPOs soar in first quarter

Survey compares 'push/pull' tactics in patient recruitment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs